The American Journal of Managed Care23 天
Postponed MacTel Treatment Approval Could Lead to Delay of Needed Care
A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment for longer than anticipated. Macular telangiectasia (MacTel) type 2 ...
Monthly Prescribing Reference1 个月
FDA Extends Review of CNTF Ocular Implant for Macular Telangiectasia
The new PDUFA target date is March 18, 2025. The Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for NT-501 (revakinagene taroretcel ...
Verywell Health on MSN6 个月
MacTel2 Treatment: With Easier Ways to Adapt to Vision Loss
Macular telangiectasia type 2 (MacTel2) causes gradual vision loss in both eyes. This condition is not curable, but ...
WebMD2 年
Vitamins by Condition
Considering taking supplements to treat macular telangiectasia type 2? Below is a list of common natural remedies used to treat or reduce the symptoms of macular telangiectasia type 2. Follow the ...
Yahoo Finance1 个月
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type ...
The new PDUFA goal date for the biologics license application (BLA) of NT-501 (revakinagene taroretcel) as a treatment for Macular telangiectasia type 2 (MacTel) is March 18, 2025. "We are ...